Kopald K H, Hiatt J R, Irving C, Giuliano A E
Department of Surgery, UCLA School of Medicine 90024.
Am Surg. 1990 Dec;56(12):782-7.
A principal goal of mammographic screening is the early detection of breast cancer. We reviewed records of 125 women who were referred because of nonpalpable, suspicious abnormalities on mammogram, which subsequently proved to be cancer, requiring mammographic localization biopsy and subsequent surgery for therapy. We found that 72 (57.6%) had invasive tumors, 15 (12%) showed evidence of microinvasion and 38 (30.4%) were noninvasive. A total of 115 patients had lymphadenectomy as part of their definitive surgery. Nine (12.7%) of the patients with infiltrating tumors had between one and 10 malignant nodes on histologic section. None of the patients with noninvasive or microinvasive tumors were found to have involved nodes. The mammographic abnormalities which led to biopsy in our series were: calcifications in 74 (59.2%) patients, mass lesions in 39 (31.2%), mass lesions with calcifications in 11 (8.8%), and asymmetry in one (0.8%). Of the nine patients with nodal metastases, seven (77.8%) had a mass with or without calcifications as the indication for biopsy. Increasing tumor size was found to correlate with invasive tumors on histopathologic examination and the incidence of lymph node metastases. Thirty-seven (54.4%) of the patients with infiltrating tumors had a tumor size greater than 1 cm. Further, seven (77.8%) of the nine lymph node positive patients had tumors between 1 and 3 cm in size. Of note, however, is that two (22.2%) patients with microscopic tumors had involved nodes. The 4-year actuarial survival in patients with infiltrating tumors was 85.2 per cent, while that for patients with noninvasive or microinvasive tumors was 100 per cent (median follow-up of 20 months).(ABSTRACT TRUNCATED AT 250 WORDS)
乳腺钼靶筛查的一个主要目标是早期发现乳腺癌。我们回顾了125名女性的记录,这些女性因钼靶检查发现不可触及的可疑异常而前来就诊,随后证实为癌症,需要进行钼靶定位活检及后续手术治疗。我们发现,72例(57.6%)为浸润性肿瘤,15例(12%)有微浸润证据,38例(30.4%)为非浸润性。共有115例患者在确定性手术中进行了淋巴结清扫。9例(12.7%)浸润性肿瘤患者在组织学切片上有1至10个恶性淋巴结。非浸润性或微浸润性肿瘤患者均未发现有淋巴结受累。在我们的系列研究中,导致活检的钼靶异常情况为:74例(59.2%)患者为钙化,39例(31.2%)为肿块病变,11例(8.8%)为伴有钙化的肿块病变,1例(0.8%)为不对称。在9例有淋巴结转移的患者中,7例(77.8%)以有或无钙化的肿块作为活检指征。在组织病理学检查中,发现肿瘤大小增加与浸润性肿瘤及淋巴结转移发生率相关。37例(54.4%)浸润性肿瘤患者的肿瘤大小大于1厘米。此外,9例淋巴结阳性患者中有7例(77.8%)的肿瘤大小在1至3厘米之间。然而,值得注意的是,2例(22.2%)微小肿瘤患者有淋巴结受累。浸润性肿瘤患者的4年精算生存率为85.2%,而非浸润性或微浸润性肿瘤患者为100%(中位随访20个月)。(摘要截断于250字)